title: Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
abstract: In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-d-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau.
authors.affiliation: University of California, San Diego, California 92093, USA. paisen@ucsd.edu
authors.forename: Paul S
authors.initials: PS
authors.lastname: Aisen
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Cummings
authors.forename: Lon S
authors.initials: LS
authors.lastname: Schneider
mesh_terms: D000470:Alkaloids / Q000627:therapeutic use; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy*; D000596:Amino Acids / Q000627:therapeutic use; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000266:history / Q000627:therapeutic use*; D019587:Dietary Supplements; D018450:Disease Progression; D004281:Docosahexaenoic Acids / Q000627:therapeutic use; D000077265:Donepezil; D017277:Drug Approval; D005702:Galantamine / Q000494:pharmacology / Q000627:therapeutic use; D020441:Ginkgo biloba; D006207:Half-Life; D049673:History, 20th Century; D006801:Humans; D007189:Indans / Q000494:pharmacology / Q000627:therapeutic use; D008559:Memantine / Q000494:pharmacology / Q000627:therapeutic use; D018697:Nootropic Agents / Q000627:therapeutic use; D048448:Phenylcarbamates / Q000494:pharmacology / Q000627:therapeutic use; D008517:Phytotherapy; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D011619:Psychotropic Drugs / Q000494:pharmacology / Q000627:therapeutic use; D018091:Receptors, AMPA / Q000187:drug effects; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects*; D000068836:Rivastigmine; D012717:Sesquiterpenes / Q000627:therapeutic use; D014803:Vitamin B Complex / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
chemical_list: D000470:Alkaloids; D000596:Amino Acids; D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D048448:Phenylcarbamates; D010880:Piperidines; D011619:Psychotropic Drugs; D018091:Receptors, AMPA; D016194:Receptors, N-Methyl-D-Aspartate; D012717:Sesquiterpenes; C050426:huperzine A; D005702:Galantamine; D014803:Vitamin B Complex; D014810:Vitamin E; D004281:Docosahexaenoic Acids; C006952:cerebrolysin; D000077265:Donepezil; D000068836:Rivastigmine; D008559:Memantine